Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Changing views on adverse event reporting.

Flores B, Klaar S, O'Connor DJ.

Lancet Haematol. 2018 Jun 12. pii: S2352-3026(18)30074-7. doi: 10.1016/S2352-3026(18)30074-7. [Epub ahead of print] No abstract available.

PMID:
29907550
2.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

3.

Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.

Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger GP, Hellborg H, Bjohle J, Borg AL, Skoog L, Bergh J.

Ann Oncol. 2007 May;18(5):845-50. Epub 2007 Mar 9.

PMID:
17351254
4.

Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes.

Wennmalm K, Calza S, Ploner A, Hall P, Bjöhle J, Klaar S, Smeds J, Pawitan Y, Bergh J.

Genes Chromosomes Cancer. 2007 Jan;46(1):87-97.

PMID:
17044045
5.

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.

Calza S, Hall P, Auer G, Bjöhle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y.

Breast Cancer Res. 2006;8(4):R34.

6.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL.

Clin Cancer Res. 2006 Feb 15;12(4):1157-67.

7.

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J.

Breast Cancer Res. 2005;7(6):R953-64. Epub 2005 Oct 3.

8.

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5. Epub 2005 Sep 2. Erratum in: Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17882.

9.

Gene profile and response to treatment.

Smeds J, Miller LD, Bjöhle J, Hall P, Klaar S, Liu ET, Pawitan Y, Ploner A, Bergh J.

Ann Oncol. 2005;16 Suppl 2:ii195-202. Review. No abstract available.

PMID:
15958456
10.

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J.

Ann Oncol. 2005 May;16(5):743-8. Epub 2005 Mar 31.

PMID:
15802278
11.

Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.

Linderholm B, Karlsson E, Klaar S, Lindahl T, Borg AL, Elmberger G, Bergh J.

Eur J Cancer. 2004 Nov;40(16):2417-23.

PMID:
15519514
12.

Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel.

Poikonen P, Sjöström J, Klaar S, Nittby LT, Sigurdsson H, Madsen EL, Joensuu H, Blomqvist C.

Acta Oncol. 2004;43(2):190-5.

PMID:
15163169
13.

Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.

Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J.

Carcinogenesis. 2004 Mar;25(3):375-80. Epub 2003 Nov 21.

PMID:
14633656
14.

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden.

Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L, Pettersson-Sköld D, Sverrisdottir A, Söderberg M, Klaar S, Bergh J.

Acta Oncol. 2002;41(3):276-81.

PMID:
12195747
15.

Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort.

Norberg T, Klaar S, Kärf G, Nordgren H, Holmberg L, Bergh J.

Cancer Res. 2001 Nov 15;61(22):8317-21.

16.

Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers.

Norberg T, Klaar S, Lindqvist L, Lindahl T, Ahlgren J, Bergh J.

Clin Chem. 2001 May;47(5):821-8.

17.

The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J.

Cancer Res. 2001 Mar 1;61(5):2256-60.

18.

Can axillary dissection be avoided by improved molecular biological diagnosis?

Lindahl T, Engel G, Ahlgren J, Klaar S, Bjöhle J, Lindman H, Andersson J, von Schoultz E, Bergh J.

Acta Oncol. 2000;39(3):319-26. Review.

PMID:
10987228

Supplemental Content

Support Center